163 related articles for article (PubMed ID: 12124882)
1. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome.
Wagner AD; Andresen J; Jendro MC; Hülsemann JL; Zeidler H
Arthritis Rheum; 2002 Jul; 46(7):1965-8. PubMed ID: 12124882
[No Abstract] [Full Text] [Related]
2. [TNF-alpha inhibitors].
Fain O
Rev Prat; 2003 Nov; 53(18):1989-90. PubMed ID: 15008210
[No Abstract] [Full Text] [Related]
3. Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome.
Hurtado-Nedelec M; Chollet-Martin S; Nicaise-Roland P; Grootenboer-Mignot S; Ruimy R; Meyer O; Hayem G
Rheumatology (Oxford); 2008 Aug; 47(8):1160-7. PubMed ID: 18559374
[TBL] [Abstract][Full Text] [Related]
4. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
[No Abstract] [Full Text] [Related]
5. The role of tumor necrosis factor inhibitors in patients with RA.
Trethewey P
JAAPA; 2002 Sep; 15(9):23-4, 27, 30 passim. PubMed ID: 12395668
[No Abstract] [Full Text] [Related]
6. Tumor necrosis factor-alpha blockers in SAPHO syndrome.
Ben Abdelghani K; Dran DG; Gottenberg JE; Morel J; Sibilia J; Combe B
J Rheumatol; 2010 Aug; 37(8):1699-704. PubMed ID: 20472920
[TBL] [Abstract][Full Text] [Related]
7. [The use of biological therapy in the SAPHO syndrome].
Sentíc M; Padjen I; Baresić M; Anić B
Lijec Vjesn; 2012; 134(1-2):58-9. PubMed ID: 22519255
[No Abstract] [Full Text] [Related]
8. Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis.
Nagashima T; Okubo-Fornbacher H; Aoki Y; Kamata Y; Kimura H; Kamimura T; Nara H; Iwamoto M; Yoshio T; Okazaki H; Minota S
J Rheumatol; 2008 May; 35(5):936-8. PubMed ID: 18464318
[No Abstract] [Full Text] [Related]
9. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.
Lourari S; Prey S; Livideanu C; Jamard B; Lamant L; Cantagrel A; Paul C
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):967-8. PubMed ID: 19192017
[No Abstract] [Full Text] [Related]
10. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
Guillevin L; Mouthon L
J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
[No Abstract] [Full Text] [Related]
11. Anti-tumour necrosis factor agents and lipid profile: a class effect?
Garcês SP; Parreira Santos MJ; Vinagre FM; Roque RM; da Silva JA
Ann Rheum Dis; 2008 Jun; 67(6):895-6. PubMed ID: 18474660
[No Abstract] [Full Text] [Related]
12. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
Coates LC; McGonagle DG; Bennett AN; Emery P; Marzo-Ortega H
Ann Rheum Dis; 2008 May; 67(5):729-30. PubMed ID: 18408116
[No Abstract] [Full Text] [Related]
13. Do tumor-necrosis-factor inhibitors prevent first cardiovascular events in patients with rheumatoid arthritis?
Kaplan MJ
Nat Clin Pract Rheumatol; 2005 Dec; 1(2):74-5. PubMed ID: 16932633
[No Abstract] [Full Text] [Related]
14. TNFalpha therapy in psoriatic arthritis and psoriasis.
Mease P
Ann Rheum Dis; 2004 Jul; 63(7):755-8. PubMed ID: 15194567
[No Abstract] [Full Text] [Related]
15. Anti-tumour necrosis factor therapy in the West Midlands.
Bartram D; Sheeran T; Price T; Mulherin D
Rheumatology (Oxford); 2004 Mar; 43(3):400; author reply 400-1. PubMed ID: 14963219
[No Abstract] [Full Text] [Related]
16. Effective co-administration of infliximab and etanercept following the failure of sequential anti-TNF agents in a patient with HLA-B27-associated arthropathy.
Sheehy C; Murphy E; Barry M
Rheumatology (Oxford); 2006 Oct; 45(10):1314-5. PubMed ID: 16837474
[No Abstract] [Full Text] [Related]
17. [Innovative therapeutic options for psoriatic arthritis: TNFalpha inhibitors].
Lehnen M; Goos M; Dissemond J
Dtsch Med Wochenschr; 2004 Mar; 129(12):634-8. PubMed ID: 15011134
[No Abstract] [Full Text] [Related]
18. Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations.
Sfikakis PP; Markomichelakis N; Alpsoy E; Assaad-Khalil S; Bodaghi B; Gul A; Ohno S; Pipitone N; Schirmer M; Stanford M; Wechsler B; Zouboulis C; Kaklamanis P; Yazici H
Rheumatology (Oxford); 2007 May; 46(5):736-41. PubMed ID: 17403712
[No Abstract] [Full Text] [Related]
19. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
[No Abstract] [Full Text] [Related]
20. Guideline for anti-TNF-alpha therapy in psoriatic arthritis.
Kyle S; Chandler D; Griffiths CE; Helliwell P; Lewis J; McInnes I; Oliver S; Symmons D; McHugh N;
Rheumatology (Oxford); 2005 Mar; 44(3):390-7. PubMed ID: 15695305
[No Abstract] [Full Text] [Related]
[Next] [New Search]
